pharmaceutical development



Clarity’s proprietary SAR Technology allows to visualise biologics as they work in the body and determine their efficiency with the highest resolution modality – Positron Emission Tomography, or PET. The Company uses this capability to develop its pipeline of therapies as well as to provide Australia’s first commercial PET imaging service to biopharmaceutical companies. The data generated is a powerful tool that helps to make informed decisions regarding product candidates that de-risk the development process.

What are radiopharmaceuticals?

Radiopharmaceuticals combine the targeting and binding properties of pharmaceuticals and the emissions from radioactive isotopes, to either diagnose or treat disease. Today radiopharmaceuticals are mostly used to provide diagnostic information about cancer and to treat some life-threatening diseases.

The Radiopharmaceutical/Nuclear medicine global market is expected to grow at a CAGR of more than 5.5% to reach $9 billion by 2020 (PRWeb 2014). Such a rapid development is driven by the increasing popularity of PET scans, growing incidences of cancer and cardiac ailments, and rising awareness and availability of radiopharmaceuticals. Novel technology and new uses of existing technologies, such as hybrid imaging, will further fuel market dynamics.

SAR Technology

Clarity utilises a range of chemical compounds called ‘chelators’, which are bound to biologics and enable them to be seen in the body through molecular PET imaging. This provides powerful data on the drug’s distribution and targeting in vivo and leads to significant cost savings by providing important information all the way through the drug development process.

Although Clarity uses a broad range of chelators based upon the drugs characteristics, Clarity’s proprietary chelators are ideally suited to therapeutic and diagnostic biologics as they are able to optimally bind isotopes of copper. For many years copper has been discussed in the literature as the “perfect pairing” due to the ideal characteristics of two isotopes, being Cu-64 and Cu-67. Cu-64 enables more precise biopharmaceutical imaging due to its half-life of 13 hours, thus producing images at suitable time points for biologics where other commercially available chelators and isotopes cannot. Cu-67 has similar energy characteristics as other isotopes used today, however the shorter half-life of 61.83 hours, or 2.5 days, provides greater flexibility for optimally dosing tumours and reducing potential side-effects.

Clarity’s molecular imaging is an essential tool in the personalised medicine field as it can be used for diagnosis, spread of disease and personalised dosing estimates, monitoring treatment response and determining if a patient is disease-free after treatment. Clarity is focussed on designing and developing therapies with companion diagnostics by sourcing promising biopharmaceuticals that are known to localise at a disease site.

Clarity’s technology also has the ability to generate targeted therapeutics by delivering high-energy isotopes or large radioactive doses to target sites to provide localised radiotherapy.

Clarity is validating its SAR Technology through the development of SARTATE™ for the treatment of neuroendocrine tumours (NETs). Success in the NETs trial will create opportunities for the technology to be used more broadly for other cancers, including children’s cancers, colorectal cancer and prostate cancers, and expand Clarity’s pipeline of assets in development.